Common Cold Clinical Trial
— PEPOfficial title:
Placebo: Physician or Pill? A Randomized Trial in a Common Cold Model Funded by NIH NCCAM Under RFA "The Placebo Effect in Clinical Practice"
Verified date | December 2014 |
Source | University of Wisconsin, Madison |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
The design and interpretation of randomized trials is intimately connected to the use of
"placebo". The nature and magnitude of placebo effects, however, is very poorly understood.
This study will assess and compare placebo effects and physician interaction effects within
a community-acquired common cold model. The goal of this study is to assess two kinds of
placebo affects and how physician interaction effects;
1. The effect of receiving blinded placebo, compared to no treatment; and
2. The effect of receiving open-label active Echinacea treatment compared to blinded
active treatment.
Status | Completed |
Enrollment | 719 |
Est. completion date | April 2013 |
Est. primary completion date | August 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 12 Years and older |
Eligibility |
Inclusion criteria: - Suspected or known cold - At least one of the following cold symptoms: nasal discharge, nasal congestion, sneezing, or sore throat - Enrolled in school, for children 12 to 17 years of age Exclusion criteria: - Pregnancy; - Symptom duration > 36 hrs - Concurrent use of antibiotics, antivirals, nasal steroids, decongestants or antihistamines; - Anticipated need for symptom-relieving meds during cold - Autoimmune/deficiency disease - History of allergic rhinitis with current eye itching/sneezing - History of asthma w/current cough/SOB - Prior study entry - Allergy to Echinacea |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin-Madison Department of Family Medicine | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Duration and severity of illness, as assessed by the Wisconsin Upper Respiratory Symptom Survey (WURSS-21) | twice daily during illness | No | |
Secondary | SF-8 general health-related quality of life | daily during illness | No | |
Secondary | perceived stress PSS-4 | daily during illness | No | |
Secondary | optimism LOT | two days after enrollment | No | |
Secondary | patient satisfaction CARE | after doctor patient interaction | Yes | |
Secondary | feeling thermometer - EuroQol VAS | daily during illness | No | |
Secondary | IL-8 (inflammatory cytokine)from nasal wash | 2 days after enrollment | No | |
Secondary | neutrophil count from nasal wash | two days after enrollment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT02451163 -
DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly
|
Phase 2 | |
Completed |
NCT01944631 -
Iota-Carrageenan Nasal Spray in Common Cold
|
Phase 4 | |
Completed |
NCT01651715 -
Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections
|
Phase 1/Phase 2 | |
Completed |
NCT00963443 -
Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold
|
Phase 3 | |
Completed |
NCT00778648 -
Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms
|
N/A | |
Completed |
NCT00032500 -
Evaluation of Echinacea for the Common Cold
|
Phase 2 | |
Not yet recruiting |
NCT05070650 -
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold
|
Phase 3 | |
Completed |
NCT04144491 -
Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda
|
N/A | |
Not yet recruiting |
NCT04073511 -
Herbal Medicine 'Eungyosan' and 'Samsoeum' for Common Cold
|
N/A | |
Completed |
NCT03189537 -
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
|
Phase 3 | |
Terminated |
NCT01964885 -
Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections
|
Phase 3 | |
Completed |
NCT01277081 -
Effect of Paracetamol on the Common Cold
|
Phase 2 | |
Completed |
NCT01728090 -
Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections
|
Phase 4 | |
Completed |
NCT00405509 -
The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years
|
N/A | |
Completed |
NCT01033526 -
Symptomatic Treatment of Common Cold Symptoms
|
Phase 4 | |
Completed |
NCT05556148 -
Otrivine: Quality of Life (QoL) Impact in a Real-World Setting
|
Phase 4 | |
Terminated |
NCT03339726 -
Randomized, Double-blind, Placebo-Controlled, Efficacy Study of a New Formulation of Phenylephrine HCL in the Common Cold
|
Phase 2 | |
Completed |
NCT01361399 -
Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold
|
Phase 3 | |
Recruiting |
NCT05244148 -
Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects
|
N/A |